Glaucoma misconceptions common among patients

Article

Patients with established glaucoma have only slightly greater knowledge of their condition than patients who are newly diagnosed.

Patients with established glaucoma have only slightly greater knowledge of their condition than patients who are newly diagnosed, according to a report published in the January/February issue of Clinical & Experimental Ophthalmology.

Helen Danesh-Meyer and colleagues from Greenelane Clinical Centre, Auckland, the Southern Eye Specialists, Christchurch and the University of Auckland, New Zealand recruited 208 glaucoma patients, 100 newly diagnosed glaucoma patients and 100 controls. Each subject completed a validated self-administered true/false questionnaire assessing glaucoma knowledge.

Established glaucoma patients had marginally but significantly (p<0.05) greater glaucoma knowledge scores than new patients. Both groups scored significantly better than the control population. Significant misconceptions regarding glaucoma include: 80% of all participants thought that topical medications could not have systemic side-effects and 48% of established glaucoma patients believed that symptoms would warn them of disease progression. One-third of new patients considered blindness to be a common outcome of glaucoma.

Glaucoma patients are likely to harbour significant misconceptions about the disease. As such, the authors of this report believe that educational materials should be tailored to address this issue.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.